This review summarizes the pharmacology and clinical trial development of vorapaxar, the only approved PAR-1 receptor antagonist for secondary prevention in atherosclerotic disease.
No takes yet. Share an insight, caveat, or question.
Reinforces vorapaxar's unique approved role in atherosclerotic secondary prevention; leaves other PAR-1 antagonists' development open.
Franchi et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: